Neglected Tropical Diseases Diagnosis Market Size, Share, Growth, and Industry Analysis, By Type (Conventional Method & Molecular/Modern Method), By Application (Clinical Labs, Hospitals /Clinics & Home Healthcare) and Regional Insights and Forecast to 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET REPORT OVERVIEW

The global Neglected Tropical Diseases Diagnosis Market size was USD 6.9794 billion in 2025, and the market is projected to touch USD 9.5102 billion by 2034, exhibiting a CAGR of 3.4% during the forecast period.

Neglected Tropical Diseases (NTD) diagnosis is a field interested in creating, implementing, and using accessible, precise, and low-cost diagnostic tools to detect infections caused by pathogens commonly found in poor and tropical areas, including dengue, schistosomiasis, and leishmaniasis disease-causing pathogens. The diagnostic products are being critical in surveillance, disease mapping, and treatment direction in inaccessible, resource-limited settings whereby routine laboratory infrastructures are frequently missing.

COVID-19 IMPACT

Market Growth Restrained by Pandemic due to Redirection of Funds and Manpower

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market's growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic critically undermined this market since it led to the significant redirection of funds and manpower, where the funds and human resources, such as healthcare workers and diagnosticians, went towards the immediate response to the pandemic. The resource diversion led to delay or cancellation of key NTD efforts, including active case identification, population-based surveys, and mass screening campaigns, which directly caused a decrease and delay in diagnostic testing and reporting of diseases, including leishmaniasis and schistosomiasis.

LATEST TRENDS

Point-of-Care (PoC) Diagnostics to Propel Market Growth

This market is now characterized by an intensive push towards decentralized, easy-to-use, and technologically decent testing to achieve the 2030 goals of elimination. The major tendencies are the increased use of the so-called Point-of-Care (PoC) diagnostics, such as Rapid Diagnostic Tests (RDTs) and portable molecular tests, which enable the diagnosis to be performed quickly and, in the field, in the endemic regions that have limited resources.

•   
•   
  

  Request a Free sample to learn more about this report

    

NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Conventional Method & Molecular/Modern Method

• Traditional Methods: This category, comprising traditional approaches, such as microscopy, serology (antibody/antigen detection), culturing of the pathogen, and biochemical approaches, had a dominant market share mainly because of its popularity and usage in the past in the labs and clinics. The traditional approaches are rather cheap and more commonly used in many medical institutions, which is why it is the primary and most accessible instrument, especially in the introduction of the disease mapping and initial diagnosis of the high-prevalence infections such as soil-transmitted helminthiasis.

• Molecular/Modern Methods: The fastest-growing segment is expected to be the Molecular/Modern Diagnostic segment and can use techniques like Polymerase Chain Reactions (PCR), Next-Generation Sequencing (NGS), and advanced point-of-care (PoC) tests, like lateral flow assays (Rapid Diagnostic Tests - RDTs) and the LAMP technology. It controlled a dominant portion in some of the recent analysis, due to the augmented research and development and requirement by the results of accuracy and speed.

By Application

Based on application the market can be categorized into Clinical Labs, Hospitals /Clinics & Home Healthcare

• Clinical Laboratories: This segment has the largest market share of the market (e.g., around 44.16% in 2024), having high levels of market penetration, a high level of procedures, and complex test abilities. Clinical and reference labs have become the centralized service provider to the market, having the required high-tech equipment and qualified staff to carry out advanced molecular diagnostics (PCR) and high-volume classic tests (microscopy, serology).

• Hospitals / Clinics: This segment is a significant point of contact with patients, screening of patients, particularly in endemic locations. A combination of traditional and fast diagnostic equipment is used to manage patients and handle triage immediately in hospitals and clinics, which often become the connection between patients in society and centralized reference laboratories. This is in search of diagnostics that are quick, user-friendly, and have minimum infrastructure, mainly the use of rapid diagnostic tests (RDT) as well as in-house microscopy.

• Home Healthcare: It is projected to grow in the fastest application area because of the increased demand and popularity of the point-of-care testing services. This change is necessitated by the necessity of bedside care of patients, increasing services of home healthcare and the compulsion to bring diagnostics nearer to afflicted and frequently distant communities.

MARKET DYNAMICS

Driving Factors

Growing Disease Burden and Global Health Programs to Drive the Market Advancement

One of the major driving factors of the Neglected Tropical Diseases Diagnosis Market Growth because of the Growing Disease Burden and Global Health Programs. This sheer human population diseased with neglected tropical diseases is an inherent motivator to the diagnosis market. NTDs impact more than a billion individuals across the world, most of whom are in low-income and tropical areas, and pose an immense, unabated need for screening and diagnostic solutions. It is this heavy burden that has been put at the center of the global health agenda, especially with the targets of NTDs being incorporated in the Sustainable Development Goals and the initiation of the NTD Road Map by WHO.

Development of Technology in Rapid and Molecular Diagnostics to Expand the Market

The market is experiencing tremendous innovation that has seen the testing being made faster, more precise and more accessible, particularly in resource-constrained environments. It is essential that new technologies of diagnosis, including highly sensitive molecular diagnostics and easy-to-use point-of-care testing devices, are developed. Such developments are enabling the decentralization of diagnosis to be done by centralized clinical laboratories to smaller clinics and even home healthcare settings.

Restraining Factor

Financially Viable Market to the Market Growth

The most important restraining factor to this market is the non-commercially attractive or financially viable market that would result in the inadequate investment in Research and Development (R&D) by the private sector. The motivation for the major pharmaceutical and biotech companies to invest heavily in the development of the new, high-quality diagnostic tests is very minimal since NTDs are severe in the poorest strata of the populations of the low- and middle-income countries who cannot afford such tests at an appealing price. Consequently, the market is heavily reliant on unpredictable donor funding, public-private partnerships, and philanthropy to drive innovation and procurement, which restricts its organic and sustained commercial growth.

Adoption of the Point-of-Care Diagnostic to the Market Growth

Opportunity

One of the major opportunity factors in this market is that there has been an increasing rate of growth and adoption of the Point-of-Care (PoC) diagnostic technologies that are key towards global elimination and eradication targets. Innovative platforms, like easy, fast diagnostic tests (RDTs) and accessible molecular diagnostics, may provide the chance to prepare precise and fast testing in resource-dependent conditions and avoid the necessity of having complex central laboratories and highly skilled staff.

This technological shift is pivotal for disease mapping, treatment monitoring, and post-elimination surveillance, thereby expanding the market by providing a practical, scalable solution to deliver diagnostics where the need is greatest, and is actively supported by global public health roadmaps like the WHO's 2021–2030 NTD road map.

Not Commercially Viable to Challenge the Market Growth

Challenge

The largest threat to this market is that the market model is not commercially viable, and thus, research development and deployment are not properly invested in. Since NTDs impact the poor and most marginalized groups in low-resource environments, the commercial motive that drives a private-based company to develop, produce, and sell new and highly sensitive diagnostics is low.

Such a market failure leads to an ongoing dependence on ageing, often insensitive, diagnostic methods (such as traditional microscopy) or a lack of quality, affordable, and regulatory-accepted Point-of-Care (PoC) testing, which is needed to view disease distribution, treatment effectiveness, and elimination in the remote locations where they are most required.

•   
•   
  Request a Free sample to learn more about this report

    

NEGLECTED TROPICAL DISEASES DIAGNOSISR MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

• North America

North America has emerged as the most dominant region in the Neglected Tropical Diseases Diagnosis Market share as its the most vulnerable to providing the necessary R&D financing and philanthropy to the market of the NTD diagnosis. The U.S. government (mainly, the National Institutes of Health (NIH) and major philanthropic groups such as the Bill and Melinda Gates Foundation) contributes approximately half of the total charitable research and development on NTD worldwide. Also, market-based pull incentives are provided to pharmaceutical companies through the United States policy instruments, including the Priority Review Voucher (PRV) system adopted by the FDA. These vouchers are used to shorten the approval of a more commercially profitable product in exchange for creating a drug or diagnostic to treat an NTD, which is a direct stimulus to R&D which would otherwise be non-viable.

• Europe

Europe plays a great role as a significant push funder of basic research and clinical trials. Specific programmes working within the European Union, such as Horizon Europe and the European and Developing Countries Clinical Trials Partnership (EDCTP), have specifically aimed at funding collaborative clinical research in neglected diseases, frequently in collaboration with European research facilities and an endemic African country. This assistance is essential in facilitating novice diagnostic tools through the expensive clinical pipeline, especially those technologies created by non-profit product development alliances. Europe is also under pressure to go with its variant of the PRV system to capitalize more on its own R&D spend and to motivate the last stages of product development.

• Asia

The influence of Asia is featured with the high disease burden, the increasing market share and the rise in the role of the manufacturer. Asia-Pacific is a major end-user market due to the high prevalence of some NTDs in the region, including dengue fever, soil-transmitted helminths, and lymphatic filariasis. This large number of cases promotes the demand for diagnostic equipment in the region. Also, some Asian nations are becoming major manufacturing centres of in vitro diagnostic (IVD) and rapid diagnostic tests (RDT) that produce a significant part of the products in global NTD control programmes, and this impacts the prices and availability of the diagnostic equipment across the globe.

KEY INDUSTRY PLAYERS

Key Players Transforming the Neglected Tropical Diseases Diagnosis Landscape through Innovation and Global Strategy

The lack of a commercial incentive, attributed to the fact that the afflicted population has a low purchasing power, defines the critical industrial effect on this market, requiring that the partnerships between the state and business (PPs) and charity should be used. Such large pharmaceutical and diagnostics companies exercise their influence not so much because of conventional commercial sales, but because of critical donation programmes of drugs and products (as in the Kigali Declaration), partnerships with non-profit Product Development Partnerships (PDPs) to develop R&D in the non-commercial sector, and using government incentives (such as the Priority Review Voucher of the U.S. FDA) to justify the investment in a non-commercial space.

List Of Market Players Profiled

• Abbott Laboratories
• Beckman Coulter/Danaher
• Bio-Rad Laboratories, Inc.
• Life Technology
• Novartis Diagnostics., Ltd.

INDUSTRIAL DEVELOPMENT

August 2024: J Mitra & Company launched the first Indian self-test kit to test dengue, the Dengue NS1 Antigen self-test kit. This new home-test product can enable people to identify the dengue NS1 antigen within the first day of symptom onset, which is paramount in early intervention and better management of dengue outbreaks.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis considers both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.